![5-α Reductase Inhibitors and Prostate Cancer Mortality: A Population-Based Cohort Study in Canada](https://oncodaily.com/pub/uploads/2024/09/9509b8f194f440778dd79c288909215b-e1725444681921.webp)
5-α Reductase Inhibitors and Prostate Cancer Mortality: A Population-Based Cohort Study in Canada
Advanced Prostate Cancer Consensus Conference (APCCC) shared a post on LinkedIn, about recent paper published in JAMA Network Open:
5-α Reductase Inhibitors and Prostate Cancer Mortality.
Authors: Robert J. Hamilton, Julian Chavarriaga, Najia Khurram, Cindy Lau, Jin Luo, Ning Liu, Maria Komisarenko, Girish Kulkarni, Christopher Wallis, David N. Juurlink, Neil Fleshner, Antonio Finelli.
”5-α Reductase Inhibitors and Prostate Cancer Mortality out on JAMA Network Open.
Population-based cohort study investigates whether the use of 5-alpha-reductase inhibitors (5-ARIs), commonly prescribed for benign prostatic hyperplasia (BPH) and known to reduce prostate cancer (PCa) risk by 25%, affects mortality in men diagnosed with clinically localized PCa.
Conducted in Canada, between 2003 and 2017, the study included 19,938 men aged 65 and older. Of these, 10.6% were 5-ARI users. After a median follow-up of nearly 9 years, the study found no significant association between prediagnostic 5-ARI use and either overall or PCa-specific mortality.
These findings provide reassurance regarding the long-term safety of 5-ARI use in patients with PCa.”
Source: Advanced Prostate Cancer Consensus Conference/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023